Raises FY25 revenue view to $1.275B-$1.355B from $1.200B-$1.280B. Consensus is for FY25 EPS $5.40 and for revenue $1.25B. Sees FY25 revenue from royalties $825M-$860M, representing growth of 44%-51% over 2024.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Therapeutics (HALO) Q2 Earnings Cheat Sheet
- Halozyme’s Promising Cancer Study: A Potential Game-Changer in Oncology
- Halozyme says EU approves new indication for Janssen’s Darzalex Faspro
- Hold Rating for Halozyme Amid CMS Pricing Uncertainty and Regulatory Concerns
- Halozyme resumed with a Neutral at Goldman Sachs